Altimmune (ALT) Research & Development (2010 - 2026)

Altimmune (ALT) has reported Research & Development for 17 consecutive years, with $16.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 2.31% year-over-year to $16.2 million; the TTM figure through Mar 2026 stood at $66.8 million (down 12.76% YoY), while the FY2025 annual figure was $66.4 million, down 19.21% from the prior year.
• Research & Development declined to $16.2 million in Q1 2026 per ALT's latest filing, from $18.4 million in the prior quarter.
• Across five years, Research & Development topped out at $21.5 million in Q1 2024 and bottomed at $13.3 million in Q2 2023.
• Historically, Research & Development has averaged $17.7 million across 5 years, with a median of $17.2 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development slumped 30.62% — and 2024, when it surged 59.62%.
• Altimmune's Research & Development stood at $19.2 million in 2022, then declined by 11.84% to $16.9 million in 2023, then gained by 16.99% to $19.8 million in 2024, then decreased by 6.94% to $18.4 million in 2025, then fell by 12.04% to $16.2 million in 2026.
• Business Quant data shows ALT's Research & Development at $16.2 million in Q1 2026, $18.4 million in Q4 2025, and $15.0 million in Q3 2025.